In their recent study, Du et al. (Aggregate 2025, e701) introduced a novel near-infrared dye, IR-780-CA, which modulates its binding to endogenous albumin for concurrent imaging of inflammation and neovascularization in murine flap models. While this approach represents a significant conceptual advance in targeted imaging, critical challenges must be addressed to translate this promise into clinical utility. This letter provides a prospective analysis highlighting key limitations and proposing constructive pathways forward. We underscore the need to validate the stability of the dye-albumin complex within the proteolytically active and redox-heterogeneous postoperative microenvironment, where signal specificity may be compromised. Furthermore, we discuss the imperative to bridge interspecies physiological gaps by validating the probe’s affinity for human serum albumin and demonstrating its efficacy in large-animal models. We also explore the promising theranostic potential of this platform for site-specific drug delivery. Addressing these outlined challenges in quantification, clinical relevance, and functional extension will be pivotal in evolving this innovative technology into a robust tool for improving outcomes in reconstructive surgery.
